Abstract: The present invention is related to a method for identifying a parvovirus mutated structural protein capable of specifically binding to a binder for an antigen, a parvovirus mutated structural protein which comprises at least one B-cell epitope heterologous to the parvovirus, a multimerc structure comprising the protein, a nucleic acid encoding the protein, a virus or cell comprising the protein, a method of preparing the protein, a medicament comprising the protein, nucleic acid or multimeric structure and its use.

Abstract: The present invention is related to a method for identifying a parvovirus mutated structural protein capable of specifically binding to a binder for an antigen, a parvovirus mutated structural protein which comprises at least one B-cell epitope heterologous to the parvovirus, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a virus or cell comprising the protein, a method of preparing the protein, a medicament comprising the protein, nucleic acid or multimeric structure and its use.

Abstract: The present invention is related to a method for identifying a parvovirus mutated structural protein capable of specifically binding to a binder for an antigen, a parvovirus mutated structural protein which comprises at least one B-cell epitope heterologous to the parvovirus, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a virus or cell comprising the protein, a method of preparing the protein, a medicament comprising the protein, nucleic acid or multimeric structure and its use.

Abstract: The present invention is related to a method for identifying a parvovirus mutated structural protein capable of specifically binding to a binder for an antigen, a parvovirus mutated structural protein which comprises at least one B-cell epitope heterologous to the parvovirus, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a virus or cell comprising the protein, a method of preparing the protein, a medicament comprising the protein, nucleic acid or multimeric structure and its use.

Abstract: Especially in order to carry out the so-called enzyme-coupled DNA hybridization test in a closed cartridge including a microfluid system, using stored dry reagents, the reagents must be dissolved in the microfluid system and transported into the measuring chamber directly before the measurement. During the dissolution of the reagents in water, air cushions that cannot reach the measuring chamber must absolutely be prevented from forming upstream of the reagent liquid. According to an embodiment of the invention, the liquid measuring sample and the liquid reagents are transported in such a way that the air cushion is directed into the waste line and the measuring sample and the reagents are then introduced into the measuring chamber without any air bubbles. In this way, measuring errors can be avoided.

Abstract: The present invention is related to a method for identifying a parvovirus mutated structural protein capable of specifically binding to a binder for an antigen, a parvovirus mutated structural protein which comprises at least one B-cell epitope heterologous to the parvovirus, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a virus or cell comprising the protein, a method of preparing the protein, a medicament comprising the protein, nucleic acid or multimeric structure and its use.

Abstract: A process is proposed for preparing a microarray including a multiplicity of analytical positions or spots and arranged on a support. The spots include probe molecules and a polymer which has been solidified to give a film. A spot is generated by applying an initially flowable spotting solution to the support, which solution includes a polymer and probe molecules, the polymer being solidified after application to the support. A spotting solution is further proposed which includes, in aqueous solution, probe molecules and a polymer which can be solidified in a non-free radical manner.